Active, Not Recruiting
A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
NCT07000149
- Conditions
- Adenocarcinoma, Advanced Clear Cell Renal Cell Carcinoma, Carcinoma, +15 more
- Locations
-
- Research Site Elizabeth Vale, Australia
- Research Site Busan, South Korea
- Research Site Seoul, South Korea